COMMUNITY

ÃÖ°íÀÇ ±â¼ú·Â°ú ÃÖ»óÀÇ Ç°Áú,
ÂøÇÑ °¡°ÝÀ¸·Î º¸´äÇÏ¿© µå¸®°Ú½À´Ï´Ù.

Ä¿¹Â´ÏƼ
Community

  • Ȩ
  • Ä¿¹Â´ÏƼ
  • ÇÁ·Î¸ð¼Ç

ÇÁ·Î¸ð¼Ç

ÇÑÁ¤±â°£ ¾Æ¹Ù¹ÙÀÌ¿À Á¦°øÇϴ Ưº°ÇÑ °¡°Ý
Á¦¸ñ Cusabio) Articles in Popular Therapeutic Targets
ÀÛ¼ºÀÚ abbabio
ÀÛ¼ºÀÏÀÚ 2021-04-22
Á¶È¸¼ö 343
If you are unable to see the message below, click here to view

Therapeutic Targets refer to a series of specific molecular targets that are associated with cancer. Knowledge of these targets is helpful for molecular dissection of the mechanism of action of drugs, and these knowledge gives assistance to guide new drugs design and the search of new targets. Here, CUSABIO offers a series of articles about therapeutic targets to help our customers in cancer research.

The Oncogene HER2: a New Target for Drug-Resistant Tumors

On March 17, 2021, a research paper entitled "Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors" [1] has attracted attention. Researchers found that the combination of MCL-1. Read More>>


NRG1 or NRG1 Fusions: an Intriguing Therapeutic Target in Diseases

On January 7, 2021, the US FDA has granted a fast track designation to Zenocutuzumab (MCLA-128) as a potential therapeutic option for patients with metastatic solid tumors harboring NRG1 gene fusions. Read More>>


TNFR1: A Multifaceted Molecule in Cancer, Another Promising Therapeutic Target for COVID-19

On January 7, 2021, a study published in the journal Cancer Research showed that TNFR1-mediated apoptosis and necrosis are associated with leukemia [1]. Read More>>


MUC16 (CA125): a Promising Predictive Marker and Therapeutic Target in Cancer

MUC16, also known as CA125, is a member of the mucin (MUC) family and belongs to the transmembrane type I. MUC16, as the largest glycoprotein in the MUC family. Read More>>


ERBB3/HER3: a New Target for Tumor Therapy, a Driver Gene of Multi-Tumors

A study published in the journal Protein & Cell attracted attention. The research found that ERBB3 mutation were closely related to tumor tolerance, and further revealed that anti-ERBB3 antibodies effectively reversed drug tolerance in gastrointestinal tumor. Read More>>


As the COVID-19 pandemic evolves, we are with you during these turbulent times. CUSABIO appreciates the critical role that you and our products play in research efforts to further scientific innovation and discovery. We know that many scientists are diligently pursuing their research throughout the pandemic. Our customer service and technical support teams are equipped to remain available to help with your research needs and answer any questions.

Kit
Protein
Antibody
Molecular Biology
CUSABIO TECHNOLOGY LLC
Postal Address: 7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Tel: 301-363-4651£¨Available 9 a.m. to 5 p.m. CST from Monday to Friday£©
Website: www.cusabio.com
© 2021 CUSABIO All Products For Research Use Only
÷ºÎÆÄÀÏ